



Vivo Biosciences Inc

Contact: Dr. Raj K Singh
Location: Birmingham, AL
Email: Rsingh@vivobiotech.com
Tel: 205-937-3024
Website: www.vivobiotech.com



Company Profile

Industry Sector: Life Sciences Biotechnology

Company Overview: VBI is an emerging, venture-backed biotech company founded in 2004. We have developed novel 3D or Mini-tissue human bioassay platforms to accelerate drug discovery, preclinical and biomedical research.

VBI's advanced technology allows rapid in vitro analysis of drug efficacy, toxicity and therapeutic endpoints – the major bottlenecks of current drug discovery pipeline. Thus, it is enormously valuable for providing critical 'Go or No-go' decisions prior to expensive clinical trials.

Target Market(s):

- Preclinical Drug Efficacy/Toxicity
- Personalized Medicine
- Functional Genomics
- Regenerative Medicine (Stem cells)

Key Value Drivers

Technology*: Patented 3D HuBiogel™ is employed to develop new in vitro human bioassay systems for real-time analysis of tumorigenesis, angiogenesis and liver toxicity. Successfully used to identify new drug candidates and for better prediction of drug activity/toxicity and therapy response in patients.

Competitive Advantage:

- § Unlike 2D cell-based assays, 3D HuBiogel assays mimic in-vivo like biology.
- § Mini-tissue assay models allow studies of both normal and disease states.
- § High value utility in accelerating drug discovery & functional genomics.
- § New 'all-human' bioassays useful across basic, preclinical & therapy arenas.

Plan & Strategy: Seeking partnership via Bio-venture funding/ Investment.

- Joint venture with Chemistry & Genomics companies

*Technology funded by the NIH/NCI and being commercialized under the NIH-CAP

Management

Leadership:


Raj Singh, PhD: Founder, President and CEO
 Lee Martin, PhD: Sr. Director, Business Develop & Marketing
 Albert LoBuglio, MD: Oncologists & Emr. Director, UAB Cancer Center
 Larry Delucas, PhD, DSc: Professor & Director, CBSE, UAB

VC Members: Linda Powers, JD: Managing Dir., Toucan Capital, MD
 Larry Greer, DSD, MBA: Managing Dir., Greer Capital, AL

Scientific Advisors & Consultants:

Norton Peet, PhD: International R&D Expert, Boston, MA
 Mina Bissell, PhD: Disting. Professor, Cancer Biology, LBNL, CA

Product Pipeline



VBI Products	Status & Plan	Time Line
HuBiogel culture kits	Sales	2008
3D Bioassays	Contract services	2008
Mini-Tumor culture kits	End-users	2009
Preclinical DD tool	Validation by Big Pharma	2010
Patient Therapy Prediction	Validation plan for FDA review	2012